Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer

PURPOSE: Clinical trials investigating therapies for metastatic breast cancer (mBC) generally use progression-free survival (PFS) as primary endpoint, which is not accepted as patient-relevant outcome within the German benefit assessment. Hence a validation of PFS as surrogate endpoint for overall s...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Breast Cancer Res Treat
Hoofdauteurs: Lux, Michael Patrick, Böhme, Sarah, Hücherig, Stephanie, Jeratsch, Ulli, Kürschner, Niclas, Lüftner, Diana
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2019
Onderwerpen:
Review
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586722/
https://ncbi.nlm.nih.gov/pubmed/31065873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05262-4
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items